PATENT CLAIM ANALYSIS

Application Number: 15780704
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-12
Patent Classification: ["514", "049000"]

Abstract:
Provided relates to pharmaceutically acceptable salts of conjugates including a chemotherapeutic drug and an amino acid or a derivative thereof, which are readily taken up by a target cell and reduce side effects induced by the chemotherapeutic drug. Further, the subject matter relates to pharmaceutically acceptable salts of conjugates comprising cytidine analog drugs and aspartic or glutamic acid and analogs thereof, pharmaceutical compositions including these conjugates and use thereof for the treatment of cancer or a pre-cancer condition or disorder.

Claim (Index 58):
The pharmaceutically acceptable salt according to  claim 47 , which is devoid of trifluoroacetic acid (TFA) as an impurity.

Metadata:
- Claim Count in Document: 59.0
- Percentile: 94.0
- Lexical Diversity: 1.57407
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['11497511', '13164204', '14061261', '12933364', '11833959']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7829266451319554
- 35 USC 102 Novelty (BERT): 0.5193207238769105
- Combined Prediction Score: 0.756566053006451
- Mean Citation Score: 239.09716
- Max Citation Score: 253.29366
- Similarity Product: 137.09564398376222

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test